Paridhy Vanniya
Kunka Mohanram Ramkumar
C. R. Srikumari Srisailapathy

Abstract

The immune system protects the inner ear from various infections. However, the fragile audiological and vestibular structures are damaged due to immune-related and inflammatory responses, thus resulting in sensorineural hearing loss. Immune-mediated sensorineural hearing loss (ISNHL) can either be of autoimmune or autoinflammatory origin, and studies have shown that ISNHL ultimately results from inflammatory responses in both the cases. Several disorders have been identified that either primarily cause hearing loss due to localized inflammation (such as Meniereu2019s disease) or as an additional manifestation resulting from systemic inflammation (as seen in Muckle-Well syndrome). Immune molecular- and patho-mechanisms have been proposed to explain ISNHL, yet it has been an enigma. A crucial mechanism leading to immune activation and inflammation involves the increased levels of NLRP3 inflammasome-associated IL-1u03b2 and TNF-u03b1, in resident macrophages of the inner ear. The presence of autoantibodies to inner ear antigens have been reported as a causative ISNHL and these antibodies also serve as diagnostic markers. Genetic-susceptibility to ISNHL in some individuals has been reported. ISNHL is reversible, where hearing and vestibular functions can be restored. Several studies have put forward therapeutic strategies to alleviate hearing impairment, by usage of immunosuppressive drugs, monoclonal antibodies, IL-1u03b2 and TNF-u03b1 antagonists, and NLRP3 inflammasome-inhibitors. Emerging approaches for treating autoimmune disease include altering gut microbiota, stem cell therapy and precision medicine. The present report reviews the various molecular- and patho-mechanisms associated with ISNHL. It further focuses on possible therapeutic targets and the relevance in application of emerging therapeutic strategies to alleviate hearing loss.

Keywords:

Immune-mediated hearing loss, ISNHL, inflammasome, IL-1u03b2, NLRP3, TNF-u03b1

VOLUME

7

,

ISSUE

1
April 2019

Correspondence

C. R. Srikumari Srisailapathy

Email

crsrikumari.paridhy@gmail.com

Received

Accepted

Published

Suggested Citation

DOI

License

This work is licensed under the Creative Commons Attribution-NonCommercial-Non-Derivatives 4.0 International License (CC BY-NC-ND 4.0). License